March 9, 2021 -- To address the cold storage challenge of messenger RNA (mRNA) vaccines, GreenLight Biosciences and TFF Pharmaceuticals have entered into a feasibility and material transfer agreement to evaluate a shelf-stable dry powder formulation of GreenLight's COVID-19 mRNA vaccine candidate.
Upon successful completion of the feasibility study, a further stage of work will include non-needle administration methods for the GreenLight mRNA vaccine candidate in a dry powder form that could be administered via a nasal spray or lung inhalation.
Under the agreement, GreenLight is delivering its COVID-19 mRNA product candidate materials to TFF with the goal of identifying an optimal formulation of the GreenLight mRNA product candidate in a dry powder form. Utilizing TFF's thin-film freezing platform, the companies will work to formulate a product that has superior stability, maintains particle size of the encapsulated mRNA as well as high encapsulation efficiency, and has rapid reconstitution characteristics for injection.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
